Skip Navigation

Publication Detail

Title: Genetic deficiency or pharmacological inhibition of soluble epoxide hydrolase ameliorates high fat diet-induced pancreatic β-cell dysfunction and loss.

Authors: Koike, Shinichiro; Hsu, Ming-Fo; Bettaieb, Ahmed; Chu, Bryan; Matsumoto, Naoki; Morisseau, Christophe; Havel, Peter J; Huising, Mark O; Hammock, Bruce D; Haj, Fawaz G

Published In Free Radic Biol Med, (2021 Aug 20)

Abstract: Pancreatic β-cells are crucial regulators of systemic glucose homeostasis, and their dysfunction and loss are central features in type 2 diabetes. Interventions that rectify β-cell dysfunction and loss are essential to combat this deadly malady. In the current study, we sought to delineate the role of soluble epoxide hydrolase (sEH) in β-cells under diet-induced metabolic stress. The expression of sEH was upregulated in murine and macaque diabetes models and islets of diabetic human patients. We postulated that hyperglycemia-induced elevation in sEH leads to a reduction in its substrates, epoxyeicosatrienoic acids (EETs), and attenuates the function of β-cells. Genetic deficiency of sEH potentiated glucose-stimulated insulin secretion in mice, likely in a cell-autonomous manner, contributing to better systemic glucose control. Consistent with this observation, genetic and pharmacological inactivation of sEH and the treatment with EETs exhibited insulinotropic effects in isolated murine islets ex vivo. Additionally, sEH deficiency enhanced glucose sensing and metabolism with elevated ATP and cAMP concentrations. This phenotype was associated with attenuated oxidative stress and diminished β-cell death in sEH deficient islets. Moreover, pharmacological inhibition of sEH in vivo mitigated, albeit partly, high fat diet-induced β-cell loss and dedifferentiation. The current observations provide new insights into the role of sEH in β-cells and information that may be leveraged for the development of a mechanism-based intervention to rectify β-cell dysfunction and loss.

PubMed ID: 34038767 Exiting the NIEHS site

MeSH Terms: Animals; Diabetes Mellitus, Type 2*/drug therapy; Diabetes Mellitus, Type 2*/genetics; Diet, High-Fat/adverse effects; Epoxide Hydrolases/genetics; Humans; Hyperglycemia*; Mice; Mice, Inbred C57BL; Pancreas

to Top